UNI-BIO SCIENCE GROUP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.085 HKD | +2.41% |
|
-1.16% | +18.06% |
| 03-27 | Uni-Bio Science Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 02-14 | Uni-Bio Science's Profit to Climb in 2023 | MT |
| Sales 2022 | 440M 56.33M 77.19M | Sales 2023 | 485M 62.01M 84.98M | Capitalization | 452M 57.83M 79.25M |
|---|---|---|---|---|---|
| Net income 2022 | 38M 4.86M 6.66M | Net income 2023 | 70M 8.96M 12.27M | EV / Sales 2022 | 0.85 x |
| Net cash position 2022 | 85.82M 10.98M 15.04M | Net cash position 2023 | 85.56M 10.95M 15M | EV / Sales 2023 | 0.76 x |
| P/E ratio 2022 |
11.9
x | P/E ratio 2023 |
6.49
x | Employees | 407 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 45.61% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +2.41% | ||
| 1 week | -1.16% | ||
| Current month | +6.25% | ||
| 1 month | +16.44% | ||
| 3 months | -12.37% | ||
| 6 months | +63.46% | ||
| Current year | +18.06% |
1 week
0.08
0.09
1 month
0.070.10
Current year
0.070.11
1 year
0.040.11
3 years
0.040.12
5 years
0.040.23
10 years
0.040.30
| Managers | Title | Age | Since |
|---|---|---|---|
Zhi Gang Zhao
CEO | Chief Executive Officer | 64 | 14-03-31 |
Wei Tian
ADM | Chief Administrative Officer | 41 | - |
Jing Li
CTO | Chief Tech/Sci/R&D Officer | 45 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Zhi Gang Zhao
CEO | Chief Executive Officer | 64 | 14-03-31 |
Da Wei Chen
BRD | Director/Board Member | 54 | 17-01-12 |
Kingsley Leung
CHM | Chairman | 37 | 13-07-07 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-02 | 0.085 | +2.41% | 1 100 000 |
| 24-04-30 | 0.083 | -5.68% | 1,540,000 |
| 24-04-29 | 0.088 | +3.53% | 5,660,000 |
| 24-04-26 | 0.085 | +7.59% | 1,700,000 |
| 24-04-25 | 0.079 | -2.47% | 7,280,000 |
Delayed Quote Hong Kong S.E., May 02, 2024 at 04:08 am
More quotes
Uni-Bio Science Group Limited is a Hong Kong-based investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company operates through four segments. In-house Chemical Pharmaceutical Products segment is engaged in the manufacture and sales of in-house chemical pharmaceutical products. Its chemical pharmaceutical products include Pinapu, among others. In-house Biological Pharmaceutical Products segment is engaged in the manufacture and sales of in-house biological pharmaceutical products. Its biological pharmaceutical products include GeneTime and GeneSoft, among others. In-house Biological Pipeline segment is engaged in the industrialization of in-house biological pipeline. Its biological pipeline products include Uni-E4 and Uni-PTH, among others. Third-party Pharmaceutical Products segment is engaged in the sales of third-party pharmaceutical products.
Sector
Pharmaceuticals
Calendar
2024-08-29
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +18.06% | 65.39M | |
| -3.93% | 86.16B | |
| +2.76% | 40.17B | |
| -16.99% | 31.47B | |
| +54.44% | 25.24B | |
| -12.54% | 15.82B | |
| -9.12% | 11.96B | |
| -15.69% | 11.89B | |
| -42.56% | 11.61B | |
| +4.87% | 8.84B |
- Stock Market
- Equities
- 690 Stock
